Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial

Montgomery, H., Hobbs, F.D.R., Padilla, F., Arbetter, D., Templeton, A., Seegobin, S., Kim, K., Campos, J.A.S., Arends, R.H., Brodek, B.H., Brooks, D., Garbes, P., Jimenez, J., Koh, G.C.K.W., Padilla, K.W., Streicher, K., Viani, R.M., Alagappan, V., Pangalos, M.N., Esser, M.T. and TACKLE study group (Wilson, P.), ORCID: 0000-0003-0207-2246, 2022. Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet Respiratory Medicine. ISSN 2213-2600

Full text not available from this repository.

Item Type:	Journal article
Publication Title:	The Lancet Respiratory Medicine
Creators:	Montgomery, H., Hobbs, F.D.R., Padilla, F., Arbetter, D., Templeton, A., Seegobin, S., Kim, K., Campos, J.A.S., Arends, R.H., Brodek, B.H., Brooks, D., Garbes, P., Jimenez, J., Koh, G.C.K.W., Padilla, K.W., Streicher, K., Viani, R.M., Alagappan, V., Pangalos, M.N., Esser, M.T. and TACKLE study group (Wilson, P.),
Publisher:	Elsevier BV
Date:	7 June 2022
ISSN:	2213-2600
Identifiers:	Number Type 10.1016/s2213-2600(22)00180-1 DOI 1566545 Other
Divisions:	Schools > School of Animal, Rural and Environmental Sciences
Record created by:	Laura Ward
Date Added:	21 Jul 2022 08:41
Last Modified:	21 Jul 2022 08:41
URI:	https://irep.ntu.ac.uk/id/eprint/46652

Actions (login required)

Edit View

Views

Downloads